Femasys (FEMY)
Catheter-based fertility diagnostics, treatment, and permanent-contraception development.
Something off on this page? Send us feedback.
Generates unit sales of catheter-based fertility and diagnostic devices and disposable kits, led by FemaSeed and FemVue. FemBloc, a permanent-birth-control system paired with FemChec, remains a U.S. investigational program that requires pivotal results and FDA authorization before commercialization.
Develops and sells catheter-based devices and disposable procedure kits for infertility diagnosis and treatment, alongside gynecologic diagnostic products. FemaSeed delivers sperm into the fallopian tube, while FemVue uses ultrasound to assess the tubes; FemSperm, FemCath, and FemCerv complement the commercial portfolio. Sales reach reproductive specialists, gynecologists, fertility clinics, women's-health organizations, and distributors.
Centers commercial execution on fitting procedures into office workflows, clinician training, product ordering, and practice adoption. The United States is the principal market, with selected distributor-led availability across Europe, Canada, and Japan.
Advances FemBloc with FemChec as an office-based permanent-birth-control system. The program remains investigational in the United States, where pivotal clinical results and FDA marketing authorization must precede commercialization.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.4M · Total debt $4.8M · Total assets $12.3M · Shareholders' equity $4.0M
- Revenue
- $331.8K
- Operating income
- −$5.1M
- Net income
- −$4.5M
No dividends on record.
| Institutions2 holders · as of Jun 30, 2026 | 0.02% | 1.8K shares | |
| Insiders9 holders · as of Aug 11, 2026 | 0.57% | 47.4K shares | |
| Strategic holders1 holder · as of Aug 31, 2026 | 7.46% | 625.0K shares | |
| Otherremainder | 91.95% | 7.70M shares |
8.38M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (8.38M in the company's Sep 3, 2026 report, 3.02M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Stonepine Capital Management, LLCStrategic | 7.46% | 625,000 | 13Gfiled Aug 31, 2026 ↗ |
Dov ElefantInsiderofficer: Chief Financial Officer | 0.19% | 15,625 | Form 4filed Aug 11, 2026 ↗ |
Kathy Lee-SepsickInsiderdirector, officer: Chief Executive Officer | 0.19% | 15,625 | Form 4filed Aug 11, 2026 ↗ |
John Charles CanningInsiderofficer: Chief Operating Officer | 0.05% | 4,375 | Form 4filed Aug 11, 2026 ↗ |
Daniel Scott CurrieInsiderofficer: Chief Operating Officer | 0.05% | 4,314 | Form 4filed Jun 4, 2025 ↗ |
| See all 23 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Jeffrey Gerald Mifek | officer: Chief Clinical-Medical Affairs | +3,125 | $3.20 |
| Aug 7, 2026 | Jeremy Alexander Sipos | officer: Chief Technology Officer | +3,125 | $3.20 |
| Aug 7, 2026 | John Charles Canning | officer: Chief Operating Officer | +4,375 | $3.20 |
| Aug 7, 2026 | Kathy Lee-Sepsick | director, officer: Chief Executive Officer | +15,625 | $3.20 |
| Aug 7, 2026 | Dov Elefant | officer: Chief Financial Officer | +15,625 | $3.20 |
- CooperCompanies
Fertility catheters and diagnostics contest office-based care.
- Organon
Long-acting Nexplanon offers a contraceptive alternative.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Femasys | $3.11 | −4.60% | $9.4M | — | — | 4.1 | −18.9% |
| CooperCompanies | $70.21 | +0.67% | $13.60B | 59.1 | 14.7 | 3.2 | +7.9% |
| Organon | $13.76 | −0.15% | $3.62B | 17.9 | 3.9 | 0.6 | −2.3% |
| Median | 38.5 | 9.3 | 1.9 | +2.8% |